10 completed, 3 recruiting, 1 unknown, 1 withdrawn. 15 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 15 | Completed 10, Recruiting 3, Unknown 1, Withdrawn 1 |
| Phase 2 | 2 | Completed 2 |
Follow Nephrosis: new trials by email Literature Review of Nephrosis trials Research Report on Nephrosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease UCAR T-cell - Autoimmune Diseases, Systemic Lupus Erthematosus (SLE) | Phase 1 | Recruiting | The Children's Hospital of Zhejiang University School of Medicine | 15 | 2025-12-01 | 2026-02-03 |
| Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cell Therapy in Patients With MDR-SRNS anti-CD19 CAR-T cells - Multi-Drug Resistant Nephrotic Syndrome, CAR-T Cell Therapy | Phase 1 | Withdrawn | The Children's Hospital of Zhejiang University School of Medicine | 2025-05-14 | 2026-06-16 | |
| Efficacy And Safety Of Azithromycin To Achieve Remissionin In Children With Steroid Sensitive Nephrotic Syndrome Azithromycin and steroids, steroids - Nephrotic Syndrome | Phase 1 | Completed | University of Child Health Sciences and Children's Hospital, Lahore | 160 | 2025-03-08 | 2026-01-06 |
| Blinatumomab for CNI-Resistant/Intolerant SRNS in Children Blinatumomab Treatment - CNI-resistant Steriod Resistant Nephrotic Syndrome, CNI-intolerent | Phase 1 | Recruiting | The Children's Hospital of Zhejiang University School of Medicine | 6 | 2024-09-19 | 2025-08-06 |
| Study of Therapeutic Efficacy of CAR-T Cell Therapy in Patients With MDR-SRNS anti-BCMA/CD70 CAR-T cells - Multi-Drug Resistant Nephrotic Syndrome, CAR-T Cell Therapy | Phase 1 | Recruiting | The Children's Hospital of Zhejiang University School of Medicine | 18 | 2024-08-13 | 2025-08-29 |
| Safety and Pharmacokinetic Study of Subcutaneous ALXN1720 in Participants With Proteinuria ALXN1720 - Proteinuria | Phase 1 | Completed | Alexion Pharmaceuticals, Inc. | 13 | 2022-06-29 | 2023-06-29 |
| A Prospective Multi-dose Study of Apixaban in Subjects With Nephrotic Syndrome Apixaban 5 MG - Nephrotic Syndrome, Membranous Nephropathy | Phase 1 | Completed | University of North Carolina, Chapel Hill | 22 | 2021-04-14 | 2023-09-26 |
| Causes and Prevention of Thromboembolic Disease in Nephrotic Syndrome Dalteparin, Apixaban - Nephrotic Syndrome, Thromboembolic Disease | Phase 1 / Phase 2 | Completed | University of Aarhus | 57 | 2021-03-25 | 2025-04-11 |
| FIH Ph 1 Study of TRPC5 Channel Inhibitor GFB-887 in Healthy Subjects GFB-887, Placebo - Healthy Volunteers | Phase 1 | Completed | Goldfinch Bio, Inc. | 70 | 2019-05-29 | 2020-06-02 |
| Pharmacokinetics of Apixaban in Nephrotic Syndrome apixaban - Nephrotic Syndrome, Proteinuria | Phase 1 | Completed | University of North Carolina, Chapel Hill | 21 | 2017-04-30 | 2019-07-24 |
| A Phase 1 Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ManNAc in Subjects With Primary Podocyte Diseases N-acetyl D-mannosamine - Kidney Disease | Phase 1 | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 10 | 2016-07-07 | 2023-02-24 |
| Allogenic AD-MSC Transplantation in Idiopathic Nephrotic Syndrome (Focal Segmental Glomerulosclerosis) Intravenous injection - Focal Segmental Glomerulosclerosis | Phase 1 | Unknown | Royan Institute | 5 | 2015-05-01 | 2015-12-04 |
| Lipid Lowering Agents to Limit Lipid Oxidation and Activation of Clotting System in Nephrotic Syndrome Pravastatin - Nephrotic Syndrome, Hyperlipidemia | Phase 1 | Completed | University of North Carolina, Chapel Hill | 7 | 2012-05-01 | 2018-08-29 |
| IL-2 for Multi Drug Resistant Nephrotic Syndrome Proleukin® - Nephrotic Syndrome | Phase 1 / Phase 2 | Completed | Istituto Giannina Gaslini | 5 | 2012-02-01 | 2015-05-28 |
| Pharmacokinetics Following Single-dose of Valsartan in Japanese Pediatric Patients Valsartan (VAL489) - Hypertension, Chronic Kidney Disease | Phase 1 | Completed | Novartis Pharmaceuticals | 12 | 2011-08-01 | 2020-12-21 |
Nephrotic Syndrome (13) · Proteinuria (5) · Glomerulosclerosis, Focal Segmental (3) · Diabetic Nephropathies (2) · Glomerulonephritis (2) · Glomerulonephritis, IGA (2) · Glomerulonephritis, Membranous (2) · Kidney Diseases (2) · Nephrosis, Lipoid (2) · Renal Insufficiency, Chronic (2) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (1) · Autoimmune Diseases (1) · Diabetes Complications (1) · Endocrine System Diseases (1) · Glomerulonephritis, Membranoproliferative (1)
Female Urogenital Diseases (15) · Female Urogenital Diseases and Pregnancy Complications (15) · Male Urogenital Diseases (15) · Urogenital Diseases (15) · Urologic Diseases (14) · Kidney Diseases (13) · Pathological Conditions, Signs and Symptoms (6) · Nephritis (5) · Signs and Symptoms (5) · Urination Disorders (5) · Urological Manifestations (5) · Glomerulonephritis (4) · Immune System Diseases (4) · Autoimmune Diseases (3)
apixaban (3) · Azithromycin (1) · Dalteparin (1) · Injections, Intravenous (1) · Interleukin-2 (1) · N-acetylmannosamine (1) · Pravastatin (1) · Steroids (1) · Valsartan (1) · aldesleukin (1)
The Children's Hospital of Zhejiang University School of Medicine (4) · University of North Carolina, Chapel Hill (3) · Alexion Pharmaceuticals, Inc. (1) · Goldfinch Bio, Inc. (1) · Istituto Giannina Gaslini (1) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1) · Novartis Pharmaceuticals (1) · Royan Institute (1) · University of Aarhus (1) · University of Child Health Sciences and Children's Hospital, Lahore (1)
United States (5) · China (3) · Denmark (1) · Iran (1) · Italy (1) · Japan (1) · Pakistan (1) · South Korea (1)
Daniel Crona, PharmD, PhD (2) · Dr. Ummara Subhani, MD (1) · Gian Marco Ghiggeri, MD (1) · Hamid Gourabi, PhD (1) · Hassan Otukesh, MD (1) · Jeanelle Kam, MD (1) · Jeffrey B Kopp, M.D. (1) · Jianhua Mao, PhD (1) · Jianhua Mao, PhD, MD (1) · Nasser Aghdami, MD,PhD (1) · Rozita Hosseini, MD (1) · Sarah Kelddal, MD (1) · Soroosh Shekarchian, MD (1) · Vimal Derebail, MD (1)
PMID 26413873, PMID 40478760, PMID 41333097, PMID 41630898, PMID 41805697, PMID 41979896
U54DK083912 (1)